|
1.參考文獻 1. Dorr W, Emmendorfer H, Haide E, Kummermehr J. Proliferation equivalent of 'accelerated repopulation' in mouse oral mucosa. International Journal of Radiation Biology. 1994;66(2):157-67. 2. Dorr W, Weber-Frisch M. Effect of changing weekly dose on accelerated repopulation during fractionated irradiation of mouse tongue mucosa. International Journal of Radiation Biology. 1995;67(5):577-85. 3. Marcu L, van Doorn T, Olver I. Modelling of post-irradiation accelerated repopulation in squamous cell carcinomas. Physics in Medicine and Biology. 2004;49(16):3767-79. 4. Liu K, Kasper M, Trott KR. Changes in keratinocyte differentiation during accelerated repopulation of the irradiated mouse epidermis. International Journal of Radiation Biology. 1996;69(6):763-9. 5. Thames HD, Ruifrok AC, Milas L, Hunter N, Mason KA, Terry NH, et al. Accelerated repopulation during fractionated irradiation of a murine ovarian carcinoma: downregulation of apoptosis as a possible mechanism. International Journal of Radiation Oncology, Biology, Physics. 1996;35(5):951-62. 6. Schmidt-Ullrich RK, Contessa JN, Dent P, Mikkelsen RB, Valerie K, Reardon DB, et al. Molecular mechanisms of radiation-induced accelerated repopulation. Radiation Oncology Investigations. 1999;7(6):321-30. 7. Corry J, Rischin D. Strategies to overcome accelerated repopulation and hypoxia--what have we learned from clinical trials? Seminars in Oncology. 2004;31(6):802-8. 8. Gospodinov A, Herceg Z. Chromatin structure in double strand break repair. DNA Repair. 2013;12(10):800-10. 9. Hubenak JR, Zhang Q, Branch CD, Kronowitz SJ. Mechanisms of injury to normal tissue after radiotherapy: a review. Plastic and Reconstructive Surgery. 2014;133(1):49e-56e. 10. Willers H, Dahm-Daphi J, Powell SN. Repair of radiation damage to DNA. British journal of cancer. 2004;90(7):1297-301. 11. Rezvani M, Hopewell JW, Morris GM, Wilding D, Whitehouse E, Robbins ME, et al. Repair, repopulation and cell cycle redistribution in rat foot skin. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 1998;46(2):193-9. 12. Williams JR, Zhang Y, Zhou H, Russell J, Gridley DS, Koch CJ, et al. Genotype-dependent radiosensitivity: clonogenic survival, apoptosis and cell-cycle redistribution. International Journal of Radiation Biology. 2008;84(2):151-64. 13. Wilson GD. Cell kinetics. Clinical Oncology. 2007;19(6):370-84. 14. Tomita N, Shibamoto Y, Ito M, Ogino H, Sugie C, Ayakawa S, et al. Biological effect of intermittent radiation exposure in vivo: recovery from sublethal damage versus reoxygenation. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2008;86(3):369-74. 15. Milas L, Hunter N, Mason KA, Milross C, Peters LJ. Tumor reoxygenation as a mechanism of taxol-induced enhancement of tumor radioresponse. Acta Oncologica. 1995;34(3):409-12. 16. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell. 2004;5(5):429-41. 17. Karroum O, Kengen J, Danhier P, Magat J, Mignion L, Bouzin C, et al. Tumor reoxygenation following administration of Mitogen-Activated Protein Kinase inhibitors: a rationale for combination with radiation therapy. Radiotherapy and oncology : Journal of the European Society for Therapeutic Radiology and Oncology. 2012;105(1):64-71. 18. Bergonié J, Tribondeau L - Interprétation de quelques résultats de la radiothérapie et essai de fixation d'une technique rationnelle. Comptes Rendus Hebdomadaires de I'Académie des Sciences, 1906, 983-985 19. Rubin P., Casarett G.W. (1968). Clinical Radiation Pathology. Philadelphia, WB Saunders. 20. NCCN Guideline of Nasopharyneal Cancer (2014Edition), National Comprehensive Cancer Network 21. Harari, Paul M., Connor, Nadine P.(2009) Functional Preservation and Quality of Life in Head and Neck Radiotherapy. Internet Society: Rosten, VA, USA., Springer.. 22. Fountzilas G, Ciuleanu E, Bobos M, Kalogera-Fountzila A, Eleftheraki AG, Karayannopoulou G, et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Annals of oncology, 2012;23(2):427-35. 23. Huang PY, Cao KJ, Guo X, Mo HY, Guo L, Xiang YQ, et al. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Oral Oncology. 2012;48(10):1038-44. 24. Huang PY, Mai HQ, Luo DH, Qiu F, Li NW, Xiang YQ, et al. Induction-concurrent chemoradiotherapy versus induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Ai Zheng Chinese Journal of Cancer. 2009;28(10):1033-42. 25. Ma L, Guo Q, Zhang Y, Kong X, Yang L, Lin S, et al. The effect of intensity-modulated radiotherapy versus conventional radiotherapy on quality of life in patients with nasopharyngeal cancer: a cross-sectional study. Head &; Neck Oncology. 2013;5(1):8. 26. Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiotherapy and oncology, 2012;104(3):286-93. 27. Zhou GQ, Yu XL, Chen M, Guo R, Lei Y, Sun Y, et al. Radiation-induced temporal lobe injury for nasopharyngeal carcinoma: a comparison of intensity-modulated radiotherapy and conventional two-dimensional radiotherapy. PloS one. 2013;8(7):e67488. 28. Gibb AG, Loh KS. The role of radiation in delayed hearing loss in nasopharyngeal carcinoma. The Journal of Laryngology and Otology. 2000;114(2):139-44. 29. Chan SH, Ng WT, Kam KL, Lee MC, Choi CW, Yau TK, et al. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. International Journal of Radiation Oncology, Biology, Physics. 2009;73(5):1335-42. 30. Wei Y, Zhou T, Zhu J, Zhang Y, Sun M, Ding X, et al. Long-term outcome of sensorineural hearing loss in nasopharyngeal carcinoma patients: comparison between treatment with radiotherapy alone and chemoradiotherapy. Cell Biochemistry and Biophysics. 2014;69(3): 433-7. 31. Hsin CH, Chen TH, Young YH, Liu WS. Comparison of otologic complications between intensity-modulated and two-dimensional radiotherapies in nasopharyngeal carcinoma patients. Otolaryngology Head and Neck surgery, 2010;143(5):662-8. 32. Soh JM, D'Souza VD, Sarepaka GK, Ng WN, Ong CS, Low WK. Cochlear Implant Outcomes: A Comparison between Irradiated and Non-irradiated Ears. Clinical and Experimental Otorhinolaryngology. 2012;5 Suppl 1:S93-8. 33. Su SF, Huang SM, Han F, Huang Y, Chen CY, Xiao WW, et al. Analysis of dosimetric factors associated with temporal lobe necrosis (TLN) in patients with nasopharyngeal carcinoma (NPC) after intensity modulated radiotherapy. Radiation Oncology. 2013;8:17. 34. Chen JL, Huang YS, Kuo SH, Chen YF, Hong RL, Ko JY, et al. Intensity-modulated radiation therapy for T4 nasopharyngeal carcinoma. Treatment results and locoregional recurrence. Strahlentherapie und Onkologie. 2013;189(12):1001-8. 35. Lam TC, Wong FC, Leung TW, Ng SH, Tung SY. Clinical outcomes of 174 nasopharyngeal carcinoma patients with radiation-induced temporal lobe necrosis. International Journal of Radiation Oncology, Biology, Physics. 2012;82(1):e57-65. 36. Common Terminology Criteria of adverse effect V3.0. (2006) National Cancer Institute, USA. 37. Tuan JK, Ha TC, Ong WS, Siow TR, Tham IW, Yap SP, et al. Late toxicities after conventional radiation therapy alone for nasopharyngeal carcinoma. Radiotherapy and Oncology, 2012;104(3):305-11. 38. Moretto F, Rampino M, Munoz F, Ruo Redda MG, Reali A, Balcet V, et al. Conventional 2D (2DRT) and 3D conformal radiotherapy (3DCRT) versus intensity-modulated radiotherapy (IMRT) for nasopharyngeal cancer treatment. La Radiologia Medica. 2014. 39. Shueng PW, Shen BJ, Wu LJ, Liao LJ, Hsiao CH, Lin YC, et al. Concurrent image-guided intensity modulated radiotherapy and chemotherapy following neoadjuvant chemotherapy for locally advanced nasopharyngeal carcinoma. Radiation Oncology. 2011;6:95. 40. Zou Y, Song T, Yu W, Zhao R, Wang Y, Xie R, et al. XRCC3 polymorphisms are associated with the risk of developing radiation-induced late xerostomia in nasopharyngeal carcinoma patients treated with intensity modulation radiated therapy. Japanese Journal of Clinical Oncology. 2014;44(3):241-8. 41. Zhang X, Yu L, Wu W, Wu X, Xiao F, Zeng G, et al. [Long-term efficacy of submandibular gland transfer for prevention of xerostomia after radiotherapy for nasopharyngeal carcinoma]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2013;27(3):128-30, 33. 42. Zhong YH, Dai J, Wang XY, Xie CH, Chen G, Zeng L, et al. Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma. Cancer Chemotherapy and Pharmacology. 2013;71(6):1577-83. 43. Chang YC, Chen SY, Ting LL, Peng SS, Wang TC, Wang TG. A 2-year follow-up of swallowing function after radiation therapy in patients with nasopharyngeal carcinoma. Archives of Physical Medicine and Rehabilitation. 2011;92(11):1814-9. 44. Ng LK, Lee KY, Chiu SN, Ku PK, van Hasselt CA, Tong MC. Silent aspiration and swallowing physiology after radiotherapy in patients with nasopharyngeal carcinoma. Head &; Neck. 2011;33(9):1335-9. 45. Wang TG, Chang YC, Chen WS, Lin PH, Hsiao TY. Reduction in hyoid bone forward movement in irradiated nasopharyngeal carcinoma patients with dysphagia. Archives of Physical Medicine and Rehabilitation. 2010;91(6):926-31. 46. Lin PH, Hsiao TY, Chang YC, Ting LL, Chen WS, Chen SC, et al. Effects of functional electrical stimulation on dysphagia caused by radiation therapy in patients with nasopharyngeal carcinoma. Supportive Care in Cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2011;19(1):91-9. 47. Tang Y, Shen Q, Wang Y, Lu K, Wang Y, Peng Y. A randomized prospective study of rehabilitation therapy in the treatment of radiation-induced dysphagia and trismus. Strahlentherapie und Onkologie. 2011;187(1):39-44. 48. Fernandez A, Brada M, Zabuliene L, Karavitaki N, Wass JA. Radiation-induced hypopituitarism. Endocrine-related cancer. 2009; 16(3): 733-72. 49. Darzy KH. Radiation-induced hypopituitarism. Current Opinion in Endocrinology, Diabetes, and Obesity. 2013;20(4):342-53. 50. Huang S, Wang X, Hu C, Ying H. Hypothalamic-pituitary-thyroid dysfunction induced by intensity-modulated radiotherapy (IMRT) for adult patients with nasopharyngeal carcinoma. Medical Oncology. 2013;30(4):710. 51. Lin Z, Wang X, Xie W, Yang Z, Che K, Wu VW. Evaluation of clinical hypothyroidism risk due to irradiation of thyroid and pituitary glands in radiotherapy of nasopharyngeal cancer patients. Journal of Medical Imaging and Radiation Oncology. 2013;57(6):713-8. 52. Siala W, Mnejja W, Abid M, Ghorbel A, Frikha M, Daoud J. Thyroid toxicity after radiotherapy of nasopharyngeal carcinoma. Annales d'endocrinologie. 2011;72(1):19-23. 53. Appelman-Dijkstra NM, Kokshoorn NE, Dekkers OM, Neelis KJ, Biermasz NR, Romijn JA, et al. Pituitary dysfunction in adult patients after cranial radiotherapy: systematic review and meta-analysis. The Journal of Clinical Endocrinology and Metabolism. 2011;96(8):2330-40. 54. Darzy KH, Shalet SM. Absence of adrenocorticotropin (ACTH) neurosecretory dysfunction but increased cortisol concentrations and production rates in ACTH-replete adult cancer survivors after cranial irradiation for nonpituitary brain tumors. The Journal of Clinical Endocrinology and Metabolism. 2005;90(9):5217-25. 55. Kalogeras KT, Nieman LK, Friedman TC, Doppman JL, Cutler GB, Jr., Chrousos GP, et al. Inferior petrosal sinus sampling in healthy subjects reveals a unilateral corticotropin-releasing hormone-induced arginine vasopressin release associated with ipsilateral adrenocorticotropin secretion. The Journal of Clinical Investigation. 1996;97(9):2045-50. 56. Kim SW, Hwang JH, Cheon JM, Park NS, Park SE, Park SJ, et al. Direct and indirect effects of androgens on survival of hematopoietic progenitor cells in vitro. Journal of Korean Medical Science. 2005;20(3):409-16. 57. Bachman E, Feng R, Travison T, Li M, Olbina G, Ostland V, et al. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. The Journal of clinical endocrinology and metabolism. 2010;95(10):4743-7. 58. Das C, Sahana PK, Sengupta N, Giri D, Roy M, Mukhopadhyay P. Etiology of anemia in primary hypothyroid subjects in a tertiary care center in Eastern India. Indian Journal of Endocrinology and Metabolism. 2012;16(Suppl 2):S361-3. 59. Li X, Misik AJ, Rieder CV, Solaro RJ, Lowen A, Fliegel L. Thyroid hormone receptor alpha 1 regulates expression of the Na+/H+ exchanger (NHE1). The Journal of Biological Chemistry. 2002;277(32):28656-62. 60. Vargas F, Moreno JM, Rodriguez-Gomez I, Wangensteen R, Osuna A, Alvarez-Guerra M, et al. Vascular and renal function in experimental thyroid disorders. European Journal of Endocrinology. 2006;154(2): 197-212. 61. Christine Waterhouse, E. Henry Keutmann and Kathryn Y. Cusson (1948). Kidney function in adrenal insufficiency. The Journal of Clinical Investigation. 1948;27(3 Pt 1):372–379 62. Svensson J, Bengtsson BA, Rosen T, Oden A, Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. The Journal of Clinical Endocrinology and Metabolism. 2004;89(7):3306-12. 63. Bulow B, Hagmar L, Eskilsson J, Erfurth EM. Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors. The Journal of Clinical Endocrinology and Metabolism. 2000;85(2):574-84. 64. Verhelst J, Mattsson AF, Luger A, Thunander M, Goth MI, Koltowska-Haggstrom M, et al. Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. European Journal of Endocrinology. 2011;165(6):881-9. 65. Fernandez-Rodriguez E, Lopez-Raton M, Andujar P, Martinez-Silva IM, Cadarso-Suarez C, Casanueva FF, et al. Epidemiology, mortality rate and survival in a homogeneous population of hypopituitary patients. Clinical Endocrinology. 2013;78(2):278-84. 66. Riedel M, Wiese A, Schurmeyer TH, Brabant G. Quality of life in patients with Addison's disease: effects of different cortisol replacement modes. Experimental and Clinical Endocrinology. 1993;101(2):106-11. 67. Johannsson G, Filipsson H, Bergthorsdottir R, Lennernas H, Skrtic S. Long-acting hydrocortisone for glucocorticoid replacement therapy. Hormone Research. 2007;68 Suppl 5:182-8. 68. Slawik M, Klawitter B, Meiser E, Schories M, Zwermann O, Borm K, et al. Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. The Journal of Clinical Endocrinology and Metabolism. 2007;92(11):4115-22. 69. Knuth UA, Honigl W, Bals-Pratsch M, Schleicher G, Nieschlag E. Treatment of severe oligospermia with human chorionic gonadotropin/human menopausal gonadotropin: a placebo-controlled, double blind trial. The Journal of Clinical Endocrinology and Metabolism. 1987;65(6):1081-7. 70. Finkel DM, Phillips JL, Snyder PJ. Stimulation of spermatogenesis by gonadotropins in men with hypogonadotropic hypogonadism. The New England Journal of Medicine. 1985;313(11):651-5. 2.參考文獻 1. Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU international. 2013;112(4):432-41. 2. Delongchamps NB, de la Roza G, Chandan V, Jones R, Sunheimer R, Threatte G, et al. Evaluation of prostatitis in autopsied prostates--is chronic inflammation more associated with benign prostatic hyperplasia or cancer? The Journal of Urology. 2008;179(5):1736-40. 3.Benaim EA, Montoya JD, Saboorian MH, Litwiller S, Roehrborn CG. Characterization of prostate size, PSA and endocrine profiles in patients with spinal cord injuries. Prostate Cancer and Prostatic Diseases. 1998;1(5):250-5. 4. Overland GB, Vatten L, Rhodes T, DeMuro C, Jacobsen G, Vada K, et al. Lower urinary tract symptoms, prostate volume and uroflow in norwegian community men. European Urology. 2001;39(1):36-41. 5. Garraway WM, Alexander FE. Prostate disease: epidemiology, natural history and demographic shifts. British Journal of Urology. 1997;79 Suppl 2:3-8. 6.Tsukamoto T, Kumamoto Y, Masumori N, Miyake H, Rhodes T, Girman CJ, et al. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. The Journal of Urology. 1995;154(2 Pt 1):391-5. 7. Yoo TK, Cho HJ. Benign prostatic hyperplasia: from bench to clinic. Korean Journal of Urology. 2012;53(3):139-48. 8. Donnell RF. Benign prostate hyperplasia: a review of the year's progress from bench to clinic. Current Opinion of Urology. 2011;21(1):22-6. 9. Resnick NM, Yalla SV. Detrusor hyperactivity with impaired contractile function. An unrecognized but common cause of incontinence in elderly patients. JAMA : the Journal of the American Medical Association. 1987;257(22):3076-81. 10. Suzuki K, Takezawa Y, Suzuki T, Honma S, Yamanaka H. Synergistic effects of estrogen with androgen on the prostate--effects of estrogen on the prostate of androgen-administered rats and 5-alpha-reductase activity. The Prostate. 1994;25(4):169-76. 11. Xiang-Yun L, Ying-Wen X, Chen-Jing X, Jiu-Jiu W, Qi P, Bo G, et al. Possible mechanism of benign prostatic hyperplasia induced by androgen-estrogen ratios in castrated rats. Indian Journal of Pharmacology. 2010;42(5):312-7. 12. Mahapokai W, Van Sluijs FJ, Schalken JA. Models for studying benign prostatic hyperplasia. Prostate Cancer and Prostatic Diseases. 2000;3(1):28-33. 13. Wu XJ, Zhi Y, Zheng J, He P, Zhou XZ, Li WB, et al. Dutasteride on benign prostatic hyperplasia: a meta-analysis on randomized clinical trials in 6460 patients. Urology. 2014;83(3):539-43. 14. Miano R, De Nunzio C, Asimakopoulos AD, Germani S, Tubaro A. Treatment options for benign prostatic hyperplasia in older men. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 2008;14(7):RA94-102. 15.Yin L, Teng J, Huang CJ, Zhang X, Xu D. Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. Journal of Endourology / Endourological Society. 2013;27(5):604-11. 16. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. The Prostate. 1984;5(5):545-57. 17. Roberts RO, Jacobson DJ, Rhodes T, Klee GG, Leiber MM, Jacobsen SJ. Serum sex hormones and measures of benign prostatic hyperplasia. The Prostate. 2004;61(2):124-31. 18. Marberger M, Roehrborn CG, Marks LS, Wilson T, Rittmaster RS. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia. The Journal of Clinical Endocrinology and Metabolism. 2006;91(4):1323-8. 19. Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. The Journal of Urology. 2004;172(4 Pt 1):1399-403. 20. Barrack ER, Bujnovszky P, Walsh PC. Subcellular distribution of androgen receptors in human normal, benign hyperplastic, and malignant prostatic tissues: characterization of nuclear salt-resistant receptors. Cancer Research. 1983;43(3):1107-16. 21. Moore AF, Povinelli MA. Specific membrane-binding of angiotensin II--the role of degradative enzymes. The Journal of Pharmacy and Pharmacology. 1979;31(6):375-7. 22. Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids. 2008;73(3):233-44. 23. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. The Prostate Supplement. 1989;2:33-50. 24. Sakamoto S, Yokoyama M, Zhang X, Prakash K, Nagao K, Hatanaka T, et al. Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid. Endocrinology. 2004;145(6):2929-40. 25. Cohen P, Nunn SE, Peehl DM. Transforming growth factor-beta induces growth inhibition and IGF-binding protein-3 production in prostatic stromal cells: abnormalities in cells cultured from benign prostatic hyperplasia tissues. The Journal of Endocrinology. 2000;164(2):215-23. 26. Lee KL, Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia. The Journal of Urology. 2004;172(5 Pt 1):1784-91. 27. Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B, et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. The Prostate. 2002;52(1):43-58. 28. Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. The Prostate. 2004;61(1):60-72. 29. Marchivie M, Guionneau P, Howard JA, Chastanet G, Letard JF, Goeta AE, et al. Structural characterization of a photoinduced molecular switch. Journal of the American Chemical Society. 2002;124(2):194-5. 30. Boehm BJ1, Colopy SA, Jerde TJ. Acute bacterial inflammation of the mouse prostate. Prostate. 2012 Feb;72(3):307-17 31. Jerde TJ1, Bushman W. IL-1 induces IGF-dependent epithelial proliferation in prostate development and reactive hyperplasia. Science Signaling. 2009 Sep 1;2(86):ra49 32.Wu K, Bonavida B. The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Critical Reviews in Immunology. 2009;29(3):241-54. 33. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 2005;24(37):5764-74. 34. Alonso-Magdalena P, Brossner C, Reiner A, Cheng G, Sugiyama N, Warner M, et al. A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(8):2859-63. 35. Slabakova E, Pernicova Z, Slavickova E, Starsichova A, Kozubik A, Soucek K. TGF-beta1-induced EMT of non-transformed prostate hyperplasia cells is characterized by early induction of SNAI2/Slug. The Prostate. 2011;71(12):1332-43. 36. Bell-Vlasov AK, Zajda J, Eldourghamy A, Malinowska E, Meyerhoff ME. Polyion Selective Polymeric Membrane-Based Pulstrode as a Detector in Flow-Injection Analysis. Analytical Chemistry. 2014. 37. Lu T, Lin WJ, Izumi K, Wang X, Xu D, Fang LY, et al. Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development. Molecular Endocrinology. 2012;26(10):1707-15. 38. Wu MT, Tzang BS, Chang YY, Chiu CH, Kang WY, Huang CH, et al. Effects of Antrodia camphorata on alcohol clearance and antifibrosis in livers of rats continuously fed alcohol. Journal of Agricultural and Food Chemistry. 2011;59(8):4248-54. 39. Wei PL, Tu SH, Lien HM, Chen LC, Chen CS, Wu CH, et al. The in vivo antitumor effects on human COLO 205 cancer cells of the 4,7-dimethoxy-5-(2-propen-1-yl)-1,3-benzodioxole (apiole) derivative of 5-substituted 4,7-dimethoxy-5-methyl-l,3-benzodioxole (SY-1) isolated from the fruiting body of Antrodia camphorate. Journal of Cancer Research and Therapeutics. 2012;8(4):532-6. 40. Chung TY, Li FY, Chang CI, Jinn TR, Tzen JT. Inhibition of Na(+)/K(+) -ATPase by antcins, unique steroid-like compounds in Antrodia camphorate. The American Journal of Chinese Medicine. 2012;40(5):953-65. 41. Meng LM, Pai MH, Liu JJ, Yeh SL. Polysaccharides from extracts of Antrodia camphorata mycelia and fruiting bodies modulate inflammatory mediator expression in mice with polymicrobial sepsis. Nutrition. 2012;28(9):942-9. 42. Du YC, Chang FR, Wu TY, Hsu YM, El-Shazly M, Chen CF, et al. Antileukemia component, dehydroeburicoic acid from Antrodia camphorata induces DNA damage and apoptosis in vitro and in vivo models. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology. 2012;19(8-9):788-96. 43. Tsai PY, Ka SM, Chang JM, Lai JH, Dai MS, Jheng HL, et al. Antroquinonol differentially modulates T cell activity and reduces interleukin-18 production, but enhances Nrf2 activation, in murine accelerated severe lupus nephritis. Arthritis and Rheumatism. 2012;64(1):232-42. 44. Tsai PY, Ka SM, Chao TK, Chang JM, Lin SH, Li CY, et al. Antroquinonol reduces oxidative stress by enhancing the Nrf2 signaling pathway and inhibits inflammation and sclerosis in focal segmental glomerulosclerosis mice. Free Radical Biology &; Medicine. 2011;50(11):1503-16. 45. Hseu YC, Huang HC, Hsiang CY. Antrodia camphorata suppresses lipopolysaccharide-induced nuclear factor-kappaB activation in transgenic mice evaluated by bioluminescence imaging. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 2010;48(8-9):2319-25. 46. Lin SY, Sheen LY, Chiang BH, Yang JS, Pan JH, Chang YH, et al. Dietary effect of Antrodia Camphorate extracts on immune responses in WEHI-3 leukemia BALB/c mice. Nutrition and Cancer. 2010;62(5):593-600. 47. Huang GJ, Huang SS, Lin SS, Shao YY, Chen CC, Hou WC, et al. Analgesic effects and the mechanisms of anti-inflammation of ergostatrien-3beta-ol from Antrodia camphorata submerged whole broth in mice. Journal of Agricultural and Food Chemistry. 2010;58(12):7445-52. 48. Huang CH, Chang CC, Lin CM, Wang ST, Wu MT, Li EI, et al. Promoting effect of Antrodia camphorata as an immunomodulating adjuvant on the antitumor efficacy of HER-2/neu DNA vaccine. Cancer Immunology, Immunotherapy : CII. 2010;59(8):1259-72. 49. Juan YS, Mannikarottu A, Chuang SM, Li S, Lin AD, Chang-Chou L, et al. Protective effect of Antrodia camphorata on bladder ischemia/reperfusion injury. International Urology and Nephrology. 2010;42(3):637-45. 50. Yang SS, Wang GJ, Wang SY, Lin YY, Kuo YH, Lee TH. New constituents with iNOS inhibitory activity from mycelium of Antrodia camphorata. Planta Medica. 2009;75(5):512-6. 51. Chiu CH, Peng CC, Ker YB, Chen CC, Lee A, Chang WL, et al. Physicochemical characteristics and anti-inflammatory activities of antrodan, a novel glycoprotein isolated from Antrodia cinnamomea mycelia. Molecules. 2013;19(1):22-40. 52. Ker YB, Peng CC, Chang WL, Chyau CC, Peng RY. Hepatoprotective Bioactivity of the Glycoprotein, Antrodan, Isolated from Antrodia cinnamomea Mycelia. PloS ONE. 2014;9(4):e93191. 53. Liu KJ, Leu SJ, Su CH, Chiang BL, Chen YL, Lee YL. Administration of polysaccharides from Antrodia camphorata modulates dendritic cell function and alleviates allergen-induced T helper type 2 responses in a mouse model of asthma. Immunology, 2010;129(3):351-62. 54. Chen YJ, Cheng PC, Lin CN, Liao HF, Chen YY, Chen CC, et al. Polysaccharides from Antrodia camphorata mycelia extracts possess immunomodulatory activity and inhibits infection of Schistosoma mansoni. International Immunopharmacology. 2008;8(3):458-67. 55. Yang CM, Zhou YJ, Wang RJ, Hu ML. Anti-angiogenic effects and mechanisms of polysaccharides from Antrodia cinnamomea with different molecular weights. Journal of Ethnopharmacology. 2009;123(3):407-12. 56. Wu YY, Chen CC, Chyau CC, Chung SY, Liu YW. Modulation of inflammation-related genes of polysaccharides fractionated from mycelia of medicinal basidiomycete Antrodia camphorata. Acta Pharmacologica Sinica. 2007;28(2):258-67. 57. Han HF, Nakamura N, Zuo F, Hirakawa A, Yokozawa T, Hattori M. Protective effects of a neutral polysaccharide isolated from the mycelium of Antrodia cinnamomea on Propionibacterium acnes and lipopolysaccharide induced hepatic injury in mice. Chemical &; Pharmaceutical Bulletin. 2006;54(4):496-500. 58. Zhang R, Su D, Zhu W, Huang Q, Liu M, Zhang Y, et al. Estrogen suppresses adipogenesis by inhibiting S100A16 expression. Journal of Molecular Endocrinology. 2014. 59. Fungfuang W, Terada M, Komatsu N, Moon C, Saito TR. Effects of estrogen on food intake, serum leptin levels and leptin mRNA expression in adipose tissue of female rats. Laboratory Animal Research. 2013;29(3):168-73. 60. Weigt C, Hertrampf T, Kluxen FM, Flenker U, Hulsemann F, Fritzemeier KH, et al. Molecular effects of ER alpha- and beta-selective agonists on regulation of energy homeostasis in obese female Wistar rats. Molecular and Cellular Endocrinology. 2013;377(1-2):147-58. 61. Gray JM, Nunez AA, Siegel LI, Wade GN. Effects of testosterone on body weight and adipose tissue: role of aromatization. Physiology &; behavior. 1979;23(3):465-9. 62. Chen WQ, Luo SH, Ll HZ, Yang H. Effects of Ganoderma lucidum polysaccharides on serum lipids and lipoperoxidation in experimental hyperlipidemic rats. China journal of Chinese Materia Medica. 2005;30(17):1358-60. 63. Wang Hong, Yin Hua-Feng, Chen Yong. Effects of polysaccharide krestin on the blood lipids and hemorheology in the rat hyperlipoproteinemic models. Chinese Journal of Gerontology, 2011;Aug: 76-8 64. Chen G, Luo YC, Li BP, Li B, Guo Y, Li Y, et al. Effect of polysaccharide from Auricularia auricula on blood lipid metabolism and lipoprotein lipase activity of ICR mice fed a cholesterol-enriched diet. Journal of Food Science. 2008;73(6):H103-8. 65. Jackson AC, Tenniswood M, Bird CE, Clark AF. Effects of androgen and estradiol administration on the weight of the ventral prostate, seminal vesicles, and testes of immature rats. Investigative Urology. 1977;14(5):351-55. 66. Berry SJ, Coffey DS, Strandberg JD, Ewing LL. Effect of age, castration, and testosterone replacement on the development and restoration of canine benign prostatic hyperplasia. The Prostate. 1986;9(3):295-302. 67. Fukabori Y, Nakano K, Ohyama A, Yamanaka H. Stimulative effect of transforming growth factor-beta on collagen synthesis by human prostatic stromal cells in vitro. International Journal of Urology. 1997;4(6):597-602. 68. Luo J, Dunn T, Ewing C, Sauvageot J, Chen Y, Trent J, et al. Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. The Prostate. 2002;51(3):189-200. 69. Hiramatsu M, Maehara I, Ozaki M, Harada N, Orikasa S, Sasano H. Aromatase in hyperplasia and carcinoma of the human prostate. The Prostate. 1997;31(2):118-24. 70. Herrmann M, Scholmerich J, Straub RH. Influence of cytokines and growth factors on distinct steroidogenic enzymes in vitro: a short tabular data collection. Annals of the New York Academy of Sciences. 2002;966:166-86. 71. Capellino S, Straub RH, Cutolo M. Aromatase and regulation of the estrogen-to-androgen ratio in synovial tissue inflammation: common pathway in both sexes. Annals of the New York Academy of Sciences, 2014, DOI:10.1111/nyas.12398
|